Drugs /

methylprednisolone

Back to Drugs List

Overview

NCI Definition [1]:
A synthetic corticosteroid with anti-inflammatory and immunomodulating properties. Methylprednisolone binds to and activates specific nuclear receptors, resulting in altered gene expression and inhibition of proinflammatory cytokine production. This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations.

Clinical Trials

View Clinical Trials for methylprednisolone

Methylprednisolone has been investigated in 14 clinical trials, of which 10 are open and 4 are closed. Of the trials investigating methylprednisolone, 6 are phase 1 (4 open), 5 are phase 2 (3 open), 2 are phase 2/phase 3 (2 open), and 1 is phase 3 (1 open).

BCR-ABL1 Fusion, t(9;22)(q34;q11), and Complex karyotype are the most frequent biomarker inclusion criteria for methylprednisolone clinical trials.

Acute lymphoblastic leukemia, acute myeloid leukemia, and multiple myeloma are the most common diseases being investigated in methylprednisolone clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Methylprednisolone
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Methylprednisolone
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating methylprednisolone and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
83-43-2, duralone, 6alpha-methylprednisolone, adlone, caberdelta m, medrone, methylprednisolonum, depo moderin, methylprednisolon, methylprednisolone, methylprednisolone, solu-medrol, pregna-1,4-diene-3,20-dione, 11,17,21-trihydroxy-6-methyl-, (6alpha,11beta)-, (6alpha,11beta)-11,17,21-trihydroxy-6-methylpregna-1,4-diene-3,20-dione, depo-nisolone, 6alpha-methylprednisolone, meprdl, delta(1)-6alpha-methylhydrocortisone, sieropresol, depo-medrol, prednilem, 1-dehydro-6alpha-methylhydrocortisone, meprolone, methylprednisolonum, medlone 21, predni-m-tablinen, methylprednisolone succinate, radilem, 19987, depmedalone, veriderm medrol, metypresol, 12619, 6alpha-methyl-11beta,17alpha,21-triol-1,4-pregnadiene-3,20-dione, 1-dehydro-6α-methylhydrocortisone, cryosolona, mega-star, medrate, methylprednisolone (substance), esametone, metypred, medrol, medrol veriderm, depmedalone, solu moderin, methylprednisolone preparation (product), 6-methylprednisolone, 6 methylprednisolone, metilprednisolona, metipred, (6α,11β)-11,17,21-trihydroxy-6-methylpregna-1,4-diene-3,20-dione, methylprednisolone preparation, summicort, prednilen, urbason, solu-medrone, methylprednisolone, firmacort, metysolon, a-methapred, asmacortone, 6-alpha-methylprednisolone preparation, metilbetasone solubile, emmetipi, wyacort, methylprednisolone [chemical/ingredient], metrocort, solpredone
NCIT ID [1]:
C647
SNOMED ID [1]:
C-A01F0

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.